Chapter 29: Managing Nonmalignant Hematologic Disorders

The core focus of this comprehensive academic chapter is the management, underlying causes, and nursing care associated with a spectrum of nonmalignant hematologic disorders, beginning with a detailed analysis of anemia, a condition defined by decreased red blood cell count or hemoglobin concentration. Anemias are generally categorized into three types: those resulting from decreased production (hypoproliferative, such as the widely prevalent iron deficiency anemia, which is often caused by chronic blood loss or inadequate diet, or megaloblastic anemias stemming from critical deficiencies in Vitamin B12 or folic acid); those resulting from increased destruction (hemolytic anemias, evidenced by elevated indirect bilirubin and reticulocyte counts); or those due to blood loss. Among hypoproliferative disorders, aplastic anemia is a life-threatening failure of the bone marrow leading to pancytopenia. Significant hemolytic conditions include Sickle Cell Disease (SCD), an inherited disorder that causes red blood cells to deform into a rigid, sickle shape when oxygen tension is low, leading to tissue ischemia, painful vaso-occlusive crises, and serious complications like acute chest syndrome and stroke, with treatment options including hydroxyurea therapy and chronic transfusion which necessitates monitoring for iron overload. Other hemolytic types discussed include thalassemias and G-6-PD deficiency, where hemolysis is triggered by specific medications or environmental factors. The chapter also details hereditary hemochromatosis, an iron overload disorder treated with therapeutic phlebotomy, and secondary polycythemia, marked by excessive red blood cells due to increased erythropoietin release in response to chronic hypoxia. Additionally, deficiencies in white blood cells are covered, notably neutropenia (lower-than-normal neutrophil count, significantly increasing infection risk) and lymphopenia. The discussion culminates with bleeding and thrombotic disorders, including conditions caused by quantitative or qualitative platelet defects, such as Immune Thrombocytopenic Purpura (ITP), which results from antiplatelet antibodies, and coagulation factor disorders like Hemophilia A (Factor VIII deficiency) and Von Willebrand Disease (vWD), the most common inherited bleeding condition. The life-threatening acquired syndrome of Disseminated Intravascular Coagulation (DIC) is explored as a dual threat involving widespread microclotting and subsequent consumption-driven hemorrhage. Finally, hypercoagulable states, or thrombophilia, whether inherited (like Factor V Leiden mutation) or acquired (like Heparin-Induced Thrombocytopenia (HIT), which requires immediate cessation of heparin), are reviewed, emphasizing the necessity of targeted anticoagulation to prevent serious venous and arterial thrombotic events.